樂
樂觀
樂觀 · 25%NVO
$87.35
情境價格
$39.050
-0.375 (-0.96%)收盤時
Loading chart…
- 最高
- 39.290
- 開盤
- 39.210
- 成交量加權均價
- 39.03
- 成交量
- 9.19M
- 市值
- 643.52B
- 最低
- 38.750
- 成交金額
- 358.62M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 1.71
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
AI 分析 of Novo Nordisk A/S (NVO)
持有Novo Nordisk A/S is currently a hold. The stock is trading at $38.83, which is below the analyst price target of $40 set by both BMO Capital and Morgan Stanley. The forward P/E ratio is 11.83, indicating a reasonable valuation, but the company faces significant risks with a projected patent cliff for its main product, semaglutide, which accounts for 75% of its sales. Additionally, the stock has seen a year-to-date change of -25.88%, suggesting a challenging market environment.
分析師評級（1）
上檔空間 +40.00%
持有
0 買進
1 持有
0 賣出
目前: 39.05
最低
42.00
平均
54.67
最高
70.00
BMO Capital
Market Perform
$40
2026-10-12
BMO Capital
2026-10-12
目標價
$40
Market Perform
Citi
中性
—
2026-10-09
Citi
2026-10-09
目標價
—
中性
Deutsche Bank
賣出
—
2026-09-22
Deutsche Bank
2026-09-22
目標價
—
賣出
Morgan Stanley
減持
$40
2026-09-11
Morgan Stanley
2026-09-11
目標價
$40
減持
HSBC
持有
—
2026-09-10
HSBC
2026-09-10
目標價
—
持有
估值指標
Novo Nordisk A/S（NVO）目前預期本益比為 11.83，5 年平均預期本益比為 25.61。
Alphio AI 對 NVO 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
持有 NVO 的大戶
事件時間軸
資訊
9.510-24CNBCBiotech Sector Recovery: Moderna Leads the Charge
9.510-22FoolBristol-Myers Squibb Maintains Stable Revenue Growth
7.010-21FoolNovo Nordisk's Outlook for the Next Decade
9.010-21FoolNovo Nordisk Reports Promising Phase 3 Results for CagriSema
5.010-20NewsfilterNovo's CagriSema Injection Shows Significant Weight Loss Potential
NVO 常見問題 —— 由 Alphio AI 解答
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Novo Nordisk A/S is currently a hold. The stock is trading at $38.83, which is below the analyst price target of $40 set by both BMO Capital and Morgan Stanley. The forward P/E ratio is 11.83, indicating a reasonable valuation, but the company faces significant risks with a projected patent cliff for its main product, semaglutide, which accounts for 75% of its sales. Additionally, the stock has seen a year-to-date change of -25.88%, suggesting a challenging market environment.
1 analysts cover NVO: 0 rate it Buy, 1 Hold and 0 Sell. The average price target is 54.67.
社群
更多 ↗
👀 Looking for the bigger upside in obesity stocks? $NVO vs. $VKTX Novo Nordisk has blockbuster drugs and an established commercial business. Viking Therapeutics is betting on a different opportunity: turning VK2735 into a contender in both oral and injectable obesity treatments. 🔥 Why $VKTX could stand out: 💊 Oral and injectable VK2735 now in Phase 3 📊 Maintenance data showed 90% of prior weight loss retained with every-other-week dosing and 85% with monthly dosing 🚀 A potential differentiator in long-term weight management ⚠️ The trade-off? VKTX has no marketed products yet, making it a higher-risk bet than NVO. 🎯 Which obesity stock offers the better opportunity? Compare the bull case for $VKTX vs. $NVO here 👇
展開
$NVO 25 years, quarterly candles chart updated. It would be fantastic to end the year with that huge bullish signal activated. This is a buy & hold stock for long term investors. 4.5% dividend.
展開
🚨 $VKTX just took a major step toward bringing its obesity pill to market! Viking Therapeutics has initiated two Phase 3 trials of oral VK2735, targeting patients with obesity both with and without Type 2 diabetes. 📊 Phase 2 results showed up to 12.2% mean weight loss in just 13 weeks, versus 1.3% with placebo. 🔥 The bigger picture? > Injectable VK2735 is already in Phase 3, with enrollment completed in both studies. > Maintenance data showed patients retained 85–90% of prior weight loss with less frequent injections. > Oral maintenance research and VK3019 add further potential to the pipeline. Competition from $LLY and $NVO is heating up, but Viking is expanding its options across oral, injectable and maintenance treatments.
展開
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。